The potentially fatal COVID-19 pandemic has been associated with a largespectrum of clinical presentations. Beyond the classical pulmonary manifestations, gastrointestinal tract-related symptoms suchas nausea, diarrhea, abdominal distention and pain have been observed in patients, as a consequence of the binding of SARS-CoV-19 to Angiotensin-converting Enzyme 2 (ACE2) receptors in the gastrointestinal (GI) tract. The early recognition ofspecific imaging features, including hepatobiliary involvement, pancreatic involvement, development of solid organ infarcts, ischemic bowel changes and vascular occlusion, plays a key role through the course of the disease. Also, suspicious symptoms, especially in critically ill patients with clinical and biochemical markers of hypovolemia, necessitate timely imaging for bleeding complications. The aim of this pictorial review is to illustrate the spectrum of the GIimaging findings in patients with COVID-19. Awareness of diagnostic imaging hallmarks is crucial to optimize the management of these patients.

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease. Accurate staging of hepatic fibrosis is pivotal for risk stratification; however, ultrasonography (US)-based elastography techniques may yield variable results across various technologies and manufacturers. The present study aimed to assess the concordance of liver stiffness (LS) measurements between two different US elastography technologies and manufacturers in patients with MASLD. Methods: This cross-sectional study included 68 postmenopausal women with MASLD. LS was measured using two-dimensional shear wave elastography (2D-SWE) on a LOGIQ™ E10 device and both 2D-SWE and point SWE (pSWE) on an Acuson Sequoia device. Hepatic steatosis was quantified using the ultrasound-guided attenuation parameter (UGAP). Results: The LS measurements were 5.0 ± 1.3 kPa with 2D-SWE on LOGIQ™ E10, 4.3 ± 1.5 kPa with 2D-SWE on Acuson Sequoia, and 3.8 ± 0.8 kPa with pSWE on Acuson Sequoia. A significant, but low correlation was found between LOGIQ™ E10 2D-SWE and Acuson Sequoia pSWE (rs = 0.25, p = 0.045), and a moderate correlation between Acuson Sequoia 2D-SWE and pSWE (rs = 0.37, p = 0.002). No correlation was shown for 2D-SWE between the two different manufacturers. Bland–Altman analysis showed moderate-to-poor agreement of LS values between the three different US elastography techniques. Conclusions: LS measurements differed across US elastography technologies and manufacturers in postmenopausal women with early-stage MASLD. These findings highlight the need to standardize existing US elastography devices before elastography-derived LS can be applied interchangeably in MASLD diagnostic algorithms.